| Article Access Statistics | | | Viewed | 9094 | | | Printed | 351 | | | Emailed | 5 | | | PDF Downloaded | 35 | | | Comments | [Add] | | | Cited by others | 12 | | |
|
Click on image for details.
|
|
| ORIGINAL ARTICLE |
|
|
|
| Year : 2010 | Volume
: 56
| Issue : 4 | Page : 262-266 |
p53, carcinoembryonic antigen and carbohydrate antigen 19.9 expression in gall bladder cancer, precursor epithelial lesions and xanthogranulomatous cholecystitis
V Agrawal1, A Goel1, N Krishnani1, R Pandey1, S Agrawal2, VK Kapoor3
1 Department of Pathology, Sanjay Gandhi, Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
2 Department of Medical Genetics, Sanjay Gandhi, Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
3 Department of Surgical Gastroenterology, Sanjay Gandhi, Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
| Date of Submission | 24-Dec-2009 |
| Date of Decision | 01-Mar-2010 |
| Date of Acceptance | 29-May-2010 |
| Date of Web Publication | 7-Oct-2010 |
Correspondence Address:
V Agrawal
Department of Pathology, Sanjay Gandhi, Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0022-3859.70933
Background : Gallbladder cancer (GBC) is the commonest gastrointestinal cancer in women of north India. Precursor epithelial lesions in GBC are known; however, the role of xanthogranulomatous (XG) inflammation in the pathogenesis of GBC is unknown. Aims : To analyze the role of precursor lesions in the pathogenesis of GBC we studied the immunohistochemical (IHC) expression of p53, carcino-embryonic antigen (CEA) and carbohydrate antigen 19.9 (CA-19.9) in GBC, chronic cholecystitis (CC), XG cholecystitis (XGC) and precursor lesions. Materials and Methods : The study included 51 GBC, 68 CC, 42 XGC and 10 normal gallbladders. All cases were evaluated for presence of precursor lesions and IHC was performed. Results : p53 immunoreactivity was found in 55% GBC, 32% of dysplasia with malignancy and in 14% of dysplasia with CC. Sixteen percent GBC had associated XG inflammation. Normal and metaplastic epithelium in CC and in XGC did not express p53. CEA expression was apical in normal and inflammatory GBs (CC, XGC), while cytoplasmic focal to diffuse positivity was seen in 82% GBC. CA-19.9 expression was seen in all cases of normal and inflammatory GBs; however, foci of antral metaplasia were negative. Seventy-five percent of GBC expressed CA-19.9; all negative cases were high-grade on histology. Conclusions : Altered CEA expression is seen in GBC as compared to normal and inflammatory gallbladders. Loss of expression of CA19.9 in antral metaplasia and poorly differentiated GBC may indicate that it is a marker of biliary differentiation. p53 over-expression seen in GBC and in dysplasia associated with malignancy and with CC suggests that p53 mutation and dysplasia are early events in the evolution of GBC. Epithelial metaplasia and XG inflammation are often associated with GBC but do not appear to play a role in its pathogenesis through the p53 pathway.
Keywords: Chronic cholecystitis, gallbladder neoplasm, immunohistochemistry, precursor lesions, xanthogranulomatous cholecystitis
How to cite this article:
Agrawal V, Goel A, Krishnani N, Pandey R, Agrawal S, Kapoor V K. p53, carcinoembryonic antigen and carbohydrate antigen 19.9 expression in gall bladder cancer, precursor epithelial lesions and xanthogranulomatous cholecystitis. J Postgrad Med 2010;56:262-6 |
How to cite this URL:
Agrawal V, Goel A, Krishnani N, Pandey R, Agrawal S, Kapoor V K. p53, carcinoembryonic antigen and carbohydrate antigen 19.9 expression in gall bladder cancer, precursor epithelial lesions and xanthogranulomatous cholecystitis. J Postgrad Med [serial online] 2010 [cited 2023 Mar 30];56:262-6. Available from: https://www.jpgmonline.com/text.asp?2010/56/4/262/70933 |
| :: Introduction | |  |
Gallbladder cancer (GBC) is the commonest gastrointestinal cancer in women in north and central India. [1],[2] Gallstone disease and chronic cholecystitis (CC) are present in about 60-90% of cases with GBC. Xanthogranulomatous cholecystitis (XGC), a variant of CC, has been reported to be associated with 3-29% of GBC. [3],[4],[5],[6] The incidence of XGC in gallstone disease is also higher in this part of the world. [3],[7] However, the role of XGC in the pathogenesis of GBC is not known. Studies have shown that abnormalities in tumor suppressor gene, p53, are involved in the pathogenesis of GBC. [12],[15],[16],[17],[18],[19],[20] However, there is paucity of studies of p53 expression in XGC. [8] Carcino-embryonic antigen (CEA) and carbohydrate antigen 19.9 (CA-19.9) have been described as serum tumor markers in gastrointestinal malignancies including GBC. Altered CEA expression has been reported in GBC. [9],[10] However, there are no reports on the expression of CA-19.9 in benign gallbladder diseases including CC and XGC.
We planned this study to determine the immunohistochemical expression of p53, CEA and CA-19.9 in GBC, CC, XGC and precursor epithelial lesions including metaplasia and dysplasia. We also studied the correlation of the expression of p53 with clinico-pathological parameters.
| :: Materials and Methods | | |
The study included 171 consecutive evaluable gallbladder (GB) specimens received in the Department of Pathology at the Sanjay Gandhi Postgraduate Institute of Medical Sciences, a tertiary level referral hospital at Lucknow in north India. The study was approved by the institutional ethics committee. The GB specimens included 51 GBC, 68 CC and 42 XGC. None of the GBC was detected incidentally. Ten normal GBs removed in surgeries with no primary GB disease, viz. pancreatico-duodenectomy for periampullary cancer, choledochal cyst excision and liver resection were included as controls. The GB was fixed in 10% buffered formalin for 6 to 12 h. Two sections each from the fundus, body and neck were taken in all non-malignant GBs. Multiple sections were taken in GBC. All GBs were evaluated for the presence of epithelial lesions including metaplasia (antral and intestinal) and dysplasia (low and high grade). In GBC the adjacent mucosa was analyzed for presence of epithelial lesions. Histological criteria for metaplasia and dysplasia were as described by Albores Saavedra et al. [11]
Immunohistochemistry (IHC) was performed using mouse monoclonal primary antibodies for p53 (Clone DO-7, 1:100 dilution, Dako Corporation, Denmark), CEA (Clone II-7, 1:100 dilution, Dako Corporation, Denmark) and CA-19.9 (Clone 116-NS-19-9, 1:100 dilution, Dako Corporation, Denmark) using labeled Streptavidin-Biotin Peroxidase method (Dako Corporation, Denmark); 3-4 ΅m thick sections after deparaffinisation in xylene were rehydrated in graded alcohol. Endogenous peroxidase was blocked using 3% H 2 O 2 in methanol. Antigen retrieval was done using microwave pretreatment in citrate buffer (pH 6.0). The sections were incubated with primary antibody for 2 h at room temperature. After washing, the sections were treated with biotinylated secondary antibody for 30 min. A streptavidin-HRP (horse-radish peroxidase) conjugate was applied for 30 min and the reaction was visualized by using DAB (diaminobenzidine) as chromogen (Dako, Denmark). Counterstaining was done by Mayer's hematoxylin. A section of colon carcinoma known to be strongly positive for p53 and CEA was included as a positive control for p53 and CEA. A section from normal GB was used as control for CA-19.9. Negative controls for immunostaining were prepared by replacing the primary antibody with non-immune rabbit serum. The pattern of distribution of CEA and CA-19.9 was studied and recorded as apical and cytoplasmic (focal or diffuse).
The p53 immunostaining was analyzed by a semi-quantitative scoring as described by Wistuba et al. [12] The intensity of staining was recorded as absent (0), mild (1), moderate (2) and intense (3) while the percentage of nuclei stained were scored as absent/<5% (0), >5 <10% (1), 10-50% (2) and >50% (3). The total score was calculated by adding the intensity score and the percentage score and ranged from 0-6. A score of >3 was considered as positive.
| :: Results | | |
The mean age was 54 years (range 26-78) in GBC (n=51), 46 years (range 16-81) in CC (n=68), and 45 years (range 21-75) in XGC (n=42). The females formed the larger proportion with M: F ratio of 1:2 in GBC, 1:1.4 in CC and 1:1.6 in XGC. Cholelithiasis was present in 67% cases of GBC and in 97% cases and 83% cases of CC and XGC respectively. Associated XGC was present in eight (16%) cases of GBC.
Evaluation of precursor epithelial lesions in the mucosa adjacent to carcinoma showed antral metaplasia in eight (16%), intestinal metaplasia in 15 (29%), low-grade dysplasia in 12 (24%) and high-grade dysplasia in 25 cases (49%). In CC, assessment for precursor epithelial lesions showed antral metaplasia in 30 (44%), intestinal metaplasia in 27 (40%), low-grade dysplasia in 17 (25%) and high-grade dysplasia in four (6%) cases. In XGC antral metaplasia was seen in 28 (67%), intestinal metaplasia in two (5%) and low-grade dysplasia in 10 (24%) cases; high-grade dysplasia was not present in any case.
All 10 cases of normal GB were p53-negative and showed apical staining for CEA. CA-19.9 was diffusely positive in the epithelium in all cases.
Significant p53 over-expression was observed in 28 of 51 GBC (55%) [Table 1] [Figure 1]. Evidence of p53 over-expression was found in two of 12 (17%) low-grade dysplasia and 10 of 25 (40%) high-grade dysplasia with an overall positivity of 32% in dysplasia [Figure 2]. No p53 expression was seen in dysplasia associated with p53-negative tumors. No p53 expression was seen in antral and intestinal metaplasia found in the mucosa adjacent to the tumor. No significant correlation was observed between p53 over-expression and clinico-pathological parameters including age, sex and cholelithiasis, histological type, tumor grade, depth of invasion and tumor stage. In CC p53 over-expression was found only in three of 21 cases (14%) of dysplasia, all of which were cases with high-grade dysplasia. p53 over-expression was not seen in low-grade dysplasia associated with CC and XGC. No p53 expression was seen in antral and intestinal metaplasia associated with CC and XGC. | Figure 1 :Intense (score 3) immunostaining for p53 in > 50% of the tumor nuclei (score 3) in GBC (total score 6) (DAB, ×200)
Click here to view |
 | Figure 2 :High-grade dysplasia associated with GBC showing intense immunostaining for p53 in > 50% of the nuclei (total score 6) (DAB, ×400)
Click here to view |
CEA immunostaining was observed in 42 of 51 GBC cases (82%). The CEA staining pattern was apical in 13 and cytoplasmic focal (15/51) to diffuse (14/51) in 29 cases [Figure 3]. CEA immunostaining was observed in 18 of 68 CC cases (27%). The CEA pattern was apical in all cases along with focal cytoplasmic in nine cases. In XGC CEA immunostaining was observed in four cases (10%) with an apical staining pattern. Diffuse cytoplasmic staining was found only in GBC. | Figure 3 :Carcino-embryonic antigen in GBC showing diffuse cytoplasmic staining along with positivity in secretions (DAB, ×400)
Click here to view |
Seventy-five percent (38) cases of GBC were CA-19.9-positive and all showed cytoplasmic staining. The adjoining GB epithelium showed diffuse CA-19.9 apical and cytoplasmic positivity in all cases; however, foci of antral metaplasia seen in eight cases showed no staining. All the CA-19.9-negative tumors (13/51) were high grade on histology and this was statistically significant (P<0.05). All cases of CC and XGC showed apical and diffuse cytoplasmic positivity for CA-19.9; however, foci of antral metaplasia were negative [Figure 4]. | Figure 4 :CA19-9 in chronic cholecystitis showing apical and cytoplasmic staining; foci of antral metaplasia are negative (DAB, ×200)
Click here to view |
| :: Discussion | | |
GBC is the fifth commonest gastrointestinal malignancy and the most common biliary tract malignancy worldwide. It is two to four times more common in females than in males and has a peak age of presentation in the sixth to eighth decades. The pathogenesis of GBC is multi-factorial. Gallstones, female sex, genetic, racial and environmental factors have been implicated. Studies suggest that epithelial changes like metaplasia and dysplasia of GB epithelium and associated conditions like CC and XGC are the possible precursor lesions for the development of GBC. [13],[14] We found an associated focal to diffuse XGC in 16% of GBC. An association of XGC with GBC has been variably reported to be 3-29% in different studies. [3],[4],[5],[6] XGC may mimic GBC at ultrasonography and grossly at surgery and often extends to adjacent structures.
Epithelial dysplasia and metaplasia have been described both in inflammatory and malignant GB; however, the incidence of dysplasia in GBC is reported to be higher. [11] We found dysplasia in the adjoining GB epithelium in 74% of GBC and in only 28% of non-malignant GB disease. Antral metaplasia and intestinal metaplasia were seen in 16% and 29% GBC, respectively. The prevalence of antral metaplasia was higher (53%) in CC including XGC. The prevalence of intestinal metaplasia in CC including XGC was however comparable to GBC (26.4%). Roa et al. observed metaplasia, dysplasia, and carcinoma in situ (CIS) in the mucosa adjacent to the cancer in 66%, 81% and 69% cases, respectively. [14] Albores-Saavedra et al., found low and high-grade dysplasia in GBC in 41% and 79% cases, respectively, and in CC in 13.5% and 3.5% cases, respectively. [11] In a study of 400 consecutive GBs, Mukopadhyay et al., found antral metaplasia, intestinal metaplasia and dysplasia in 238 (59.5%), 39 (9.8%), and 20 (5%) cases, respectively. [13]
p53, a tumor suppressor gene, plays an important role in the genesis of many cancers. The reported incidence of p53 over-expression in GBC is variable (20-92%). [12],[15],[16],[17],[18],[19],[20] We observed significant p53 positivity (score >3) in 55% (28/51) GBC. Roa et al. in a study of 157 primary GBC, found p53 over-expression in 45% tumors. [18] A previous Indian study has reported it to be 70%. [19] There are few reports on the expression of p53 in precursor lesions of GBC. [12],[15],[16],[17] We found p53 over-expression in dysplasia associated with both GBC and CC. In dysplasia associated with GBC, p53 over-expression was seen in 17% of low-grade dysplasia and 40% of high-grade dysplasia. The dysplasia associated with CC showed p53 over-expression in 14%. Normal GB and metaplastic and non-metaplastic epithelium in malignant and non-malignant GB including XGC was negative for p53. Takada et al., found no abnormality in XGC as compared to GBC in polymerase chain reaction amplification studies for mutation of p53. [8] They suggested that the etio-pathologic factors of XGC might have relation with cancer, but XGC itself may not be the direct cause for cancer. Wistuba et al., found p53 over-expression in 44.7% CIS and 32.4% dysplasia in GBC and observed no expression in normal and metaplastic epithelium. [12] Wee et al., observed p53 over-expression in 28% while Kamel et al., observed it in 25% dysplasia in GBC. [16],[17] Although an occasional study has reported significant correlation between p53 over-expression and presence of gallstones, tumor stage, tumor grade and liver invasion, we observed no significant correlation between p53 over-expression in GBC and clinical parameters including age, gender, histological type and tumor grade, depth of invasion and tumor stage. [19] Other studies have also shown similar results. [12],[15],[21]
There is limited information on the expression patterns of CEA in GBC. [22],[23],[24] In our study, apical to focal cytoplasmic CEA expression was seen in 55% of GBC, 27% of CC and 10% of XGC. However, diffuse cytoplasmic expression of CEA was seen only in GBC (14/51, 27.5%). Albores Saavedra et al., using both rabbit and goat antibodies to analyze CEA expression in GBs, also observed diffuse cytoplasmic staining in GBC as compared to apical staining in normal GB epithelium. [22]
Serum CA-19.9 is employed as a tumor marker to discriminate patients of GBC from patients with gallstones and no cancer. [25] The expression of CA-19.9 protein in GBC has not been studied. We observed apical and cytoplasmic expression of CA-19.9 in all normal GB, CC, XGC and 75% GBC. All CA-19.9-negative GBC were of high tumor grade on histology (P<0.05). CA-19.9 expression was not seen in the foci of antral metaplasia associated with both GBC and non-malignant GB. The absence of CA-19.9 expression in the foci of antral metaplasia in malignant and non-malignant GBs and also in poorly differentiated GBC may be explained by the loss of biliary differentiation in these lesions.
We observed a high incidence of p53 over-expression in GBC and in dysplasia associated with GBC as well as CC, suggesting that dysplasia is an important and early event in the pathogenesis and development of GBC. Moreover, the increasing incidence of p53 over-expression from dysplasia to invasive tumor provides further support to the view that this may be the usual route for the development of invasive GBC.
In an earlier publication, we have found higher genomic instability in FHIT (fragile histidine triad) gene in the form of MSI (micro-satellite instability) and LOH (loss of heterozygosity) in both XGC and CC and no instability in normal GB; we hypothesized that both XGC and CC may be steps in the etiopathogenesis of GBC. [26] Our current findings suggest that though epithelial metaplasia and XG inflammation are often associated with GBC they do not appear to play a role in its pathogenesis through the p53 pathway.
| :: Acknowledgment | | |
We acknowledge the technical support of Lab technician Mr. Vishwakarma for performing immunohistochemistry.
| :: References | | |
| 1. | Dhir V, Mohandas KM. Epidemiology of digestive tract cancers in India IV. Gall bladder and pancreas. Indian J Gastroenterol 1999;18:24-8.  [PUBMED] |
| 2. | Kapoor VK, McMichael AJ. Gallbladder cancer: An 'Indian' disease'. Natl Med J India 2003;16:209-13. [PUBMED] |
| 3. | Rao RV, Kumar A, Sikora SS, Saxena R, Kapoor VK. Xanthogranulomatous cholecystitis: Differentiation from associated gall bladder carcinoma. Trop Gastroenterol 2005;26:31-3. [PUBMED] |
| 4. | Guzman-Valdivia G. Xanthogranulomatous cholecystitis: 15 years' experience. World J Surg 2004;28:254-7. |
| 5. | Benbow EW. Xanthogranulomatous cholecystitis associated with carcinoma of the gallbladder. Postgrad Med J 1989;65:528-31. [PUBMED] [FULLTEXT] |
| 6. | Yamaguchi K, Enjoji M. Carcinoma of the gallbladder. A clinicopathology of 103 patients and a newly proposed staging. Cancer 1988;62:1425-32. [PUBMED] |
| 7. | Solanki RL, Arora HL, Gaur SK, Anand V, Gupta r. Xanthogranulomatous cholecystitis (XGC): A clinicopathological study of 21 cases. Indian J Pathol Microbiol 1989;32:256-60. |
| 8. | Takada M, Horita Y, Okuda S, Okumoto S, Samizo M, Wada T, et al. Genetic analysis of xanthogranulomatous cholecystitis: Precancerous lesion of gallbladder cancer? Hepatogastroenterology 2002;49:935-7. [PUBMED] |
| 9. | Albores-Saavedra J, Nadji M, Morales AR, Henson DE. Carcinoembryonic antigen in normal, preneoplastic and neoplastic gallbladder epithelium. Cancer 1983;52:1069-72. [PUBMED] |
| 10. | Dowaki S, Kijima H, Kashiwagi H, Ohtani Y, Tobita K, Tsukui M, et al. CEA immunohistochemical localization is correlated with growth and metastasis of human gallbladder carcinoma. Int J Oncol 2000;16:49-53. [PUBMED] |
| 11. | Albores-Saavedra J, Alcantra-Vazquez A, Cruz-Ortiz H, Herrera-Goepfert R. The precursor lesions of invasive gallbladder carcinoma. Hyperplasia, atypical hyperplasia and carcinoma in situ. Cancer 1980;45:919-27. |
| 12. | Wistuba II, Gazdar AF, Roa I, Albores-Saavedra J. p53 protein overexpression in gallbladder carcinoma and its precursor lesions: An immunohistochemical study. Hum Pathol 1996;27:360-5. [PUBMED] |
| 13. | Mukhopadhyay S, Landas SK. Putative precursors of gallbladder dysplasia: A review of 400 routinely resected specimens. Arch Pathol Lab Med 2005;129:386-90. [PUBMED] [FULLTEXT] |
| 14. | Roa l, de Aretxabala X, Araya JC, Roa J. Preneoplastic lesions in gallbladder cancer. J Surg Oncol 2006;93:615-23. |
| 15. | Ajiki T, Onoyama H, Yamamoto M, Asaka K, Fujimori T, Maeda S, et al. p53 protein expression and prognosis in gallbladder carcinoma and premalignant lesions. Hepatogastroenterology 1996;43:521-6. [PUBMED] |
| 16. | Wee A, Teh M, Raju GC. Clinical importance of p53 protein in gall bladder carcinoma and its precursor lesions. J Clin Pathol 1994;47:453-6. [PUBMED] [FULLTEXT] |
| 17. | Kamel D, Paakko P, Nuorva K, Vδhδkangas K, Soini Y. p53 and c-erb-2 protein expression in adenocarcinoma and epithelial dysplasia of the gallbladder. J Pathol 1993;170:67-72. |
| 18. | Roa I, Villaseca M, Araya J, Roa J, Aretxabala X, Melo A, et al. p53 tumor suppressor gene protein expression in early and advanced gallbladder carcinoma. Histopathology 1997;31:226-30. [PUBMED] |
| 19. | Misra S, Chaturvedi A, Goel MM, Mehrotra R, Sharma ID, Srivastava AN, et al. Overexpression of p53 protein in gallbladder carcinoma in North India. Eur J Surg Oncol 2000;26:164-7. [PUBMED] [FULLTEXT] |
| 20. | Chaube A, Tewari M, Garbyal RS, Singh U, Shukla HS. Preliminary study of p53 and c-erb B-2 expression in gall bladder cancer in Indian patients. BMC Cancer 2006;10:126-8. |
| 21. | Kim YW, Huh SH, Park YK, Yoon TY, Lee SM, Hong SH. Expression of the c-erb-B2 and p53 protein in gallbladder carcinomas. Oncol Rep 2001;8:1127-32. [PUBMED] |
| 22. | Albores-Saavedra J, Nadji M, Morales AR, Henson DE. Carcinoembryonic antigen in normal, preneoplastic and neoplastic gallbladder epithelium. Cancer 1983;52:1069-72. [PUBMED] |
| 23. | Dowaki S, Kijima H, Kashiwagi H, Ohtani Y, Tobita K, Tsukui M, et al. CEA immunohistochemical localization is correlated with growth and metastasis of human gallbladder carcinoma. Int J Oncol 2000;16:49-53. [PUBMED] |
| 24. | Kanthan R, Radhi JM, Kanthan SC. Gallbladder carcinomas: An immunoprognostic evaluation of p53, Bcl-2, CEA and alpha-fetoprotein. Can J Gastroenterol 2000;14:181-4. [PUBMED] [FULLTEXT] |
| 25. | Shukla VK, Gurubachan, Sharma D, Dixit VK, Usha. Diagnostic value of serum CA242, CA 19-9, CA 15-3 and CA 125 in patients with carcinoma of the gallbladder. Trop Gastroenterol 2006;27:160-5. [PUBMED] |
| 26. | Priya T, Kapoor VK, Krishnani N, Agrawal V, Agrawal S. Fragile histidine triad (FHIT) gene and its association with p53 expression in the progression of gall bladder cancer. Cancer Invest 2009;27:764-73. |
[Figure 1], [Figure 2], [Figure 3], [Figure 4]
[Table 1]
| This article has been cited by | | 1 |
High level of tumor marker CA19-9 returned to normal after cholecystectomy in calculous cholecystitis patients |
|
| Wanjin Chen, Shouwen Wang, Hongchuan Zhao, Guobin Wang, Rong Qin, Fan Huang, Wei Geng, Zimei Liu, Wei Wang, Ruolin Wu, Liujin Hou, Zhenghui Ye, Xinghua Zhang, Xiaoping Geng, Xiaojun Yu | | Scandinavian Journal of Gastroenterology. 2023; : 1 | | [Pubmed] | [DOI] | | | 2 |
Understanding the mechanisms of gallbladder lesions: A systematic review |
|
| Andrei Bojan, Liliana Foia, Maria Vladeanu, Iris Bojan, Carmen Plesoianu, Alexandru Plesoianu, Catalin Pricop | | Experimental and Therapeutic Medicine. 2022; 24(3) | | [Pubmed] | [DOI] | | | 3 |
Presentation and surgical management of xanthogranulomatous cholecystitis |
|
| Maximos Frountzas, Dimitrios Schizas, Efstathia Liatsou, Konstantinos P Economopoulos, Christina Nikolaou, Konstantinos G Apostolou, Konstantinos G Toutouzas, Evangelos Felekouras | | Hepatobiliary & Pancreatic Diseases International. 2021; 20(2): 117 | | [Pubmed] | [DOI] | | | 4 |
Choledochal Cysts Resected during Childhood Show No Mutations of KRAS and BRAF as Early Markers of Malignancy in Cholangiocytes |
|
| Marie Uecker, Ulrich Lehmann, Peter Braubach, Nagoud Schukfeh, Omid Madadi-Sanjani, Benno M. Ure, Claus Petersen, Joachim F. Kuebler | | European Journal of Pediatric Surgery. 2021; 31(01): 020 | | [Pubmed] | [DOI] | | | 5 |
Novel immunotherapy strategies for hepatobiliary cancers |
|
| Thomas T DeLeon, Yumei Zhou, Bolni M Nagalo, Raquel T Yokoda, Daniel H Ahn, Ramesh K Ramanathan, Marcela A Salomao, Bashar A Aqel, Amit Mahipal, Tanios S Bekaii-Saab, Mitesh J Borad | | Immunotherapy. 2018; 10(12): 1077 | | [Pubmed] | [DOI] | | | 6 |
Xanthogranulomatous cholecystitis: A clinicopathological study of its association with gallbladder carcinoma |
|
| Peng Yuan Zhuang,Ming Jie Zhu,Jian Dong Wang,Xue Ping Zhou,Zhi Wei Quan,Jun Shen | | Journal of Digestive Diseases. 2013; 14(1): 45 | | [Pubmed] | [DOI] | | | 7 |
Xanthogranulomatous cholecystitis: a European and global perspective |
|
| Matthew David Hale,Keith J Roberts,James Hodson,Nigel Scott,Maria Sheridan,Giles J Toogood | | HPB. 2013; : n/a | | [Pubmed] | [DOI] | | | 8 |
Xanthogranulomatous cholecystitis: A clinicopathological study of its association with gallbladder carcinoma |
|
| Zhuang, P.Y. and Zhu, M.J. and Wang, J.D. and Zhou, X.P. and Quan, Z.W. and Shen, J. | | Journal of Digestive Diseases. 2013; 14(1): 45-50 | | [Pubmed] | | | 9 |
Diagnosis and management of gallbladder cancer |
|
| Andrén-Sandberg, A. | | North American Journal of Medical Sciences. 2012; 4(7): 293-299 | | [Pubmed] | | | 10 |
Gallbladder cancer: Can newer insights improve the outcome? |
|
| Dutta, U. | | Journal of Gastroenterology and Hepatology. 2012; 27(4): 642-653 | | [Pubmed] | | | 11 |
Gallbladder cancer: Can newer insights improve the outcome? |
|
| Usha Dutta | | Journal of Gastroenterology and Hepatology. 2012; 27(4): 642 | | [Pubmed] | [DOI] | | | 12 |
Gallbladder mucosal changes associated with chronic cholecystitis and their relationship with carcinoma gallbladder |
|
| Kaur, A. and Dubey, V.K. and Mehta, K.S. | | JK Science. 2011; 14(2): 89-92 | | [Pubmed] | |
|
|
|
|
|
|
|
|
